Data Insights

Bomedemstat tosylate by Merck for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Bomedemstat tosylate by Merck for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Relapsed Acute Myeloid Leukemia

Data Insights

Bomedemstat tosylate by Merck for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Refractory Acute Myeloid Leukemia

Data Insights

Bomedemstat tosylate by Merck for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Bomedemstat tosylate by Merck for Myelofibrosis: Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Myelofibrosis

Data Insights

Bomedemstat tosylate by Merck for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)

Data Insights

Bomedemstat tosylate by Merck for Essential Thrombocythemia: Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase III for Essential Thrombocythemia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Essential Thrombocythemia

Data Insights

Bomedemstat tosylate by Merck for Polycythemia Vera: Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Polycythemia Vera. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Polycythemia Vera

Data Insights

Bomedemstat tosylate by Merck for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Bomedemstat tosylate is under clinical development by Merck and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Bomedemstat Tosylate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Risk adjusted net present value: What is the current valuation of Merck's Bomedemstat tosylate?

Bomedemstat tosylate is a small molecule commercialized by Merck, with a leading Phase III program in Essential Thrombocythemia. According to...

Net Present Value Model: Merck & Co Inc's Bomedemstat tosylate

Data Insights

Bomedemstat tosylate by Imago BioSciences for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Bomedemstat tosylate is under clinical development by Imago BioSciences and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According...

Data Insights

Bomedemstat tosylate by Imago BioSciences for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Bomedemstat tosylate is under clinical development by Imago BioSciences and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)....